Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Condition(s) studied
Investigational drug(s) / intervention(s)
Dapagliflozin 10 mg: Dapagliflozin 10 mg will be added in addition to standard of care
Study summary
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. The main questions it aims to answer are:
1. Does dapagliflozin reduce the rate of decline in kidney function or progression to end-stage kidney disease in adults with advanced CKD?
2. Does dapagliflozin reduce the risk of death from cardiovascular or renal causes in patients with advanced CKD?
Researchers will compare dapagliflozin to a placebo to see if dapagliflozin improves kidney and cardiovascular outcomes in this high-risk population.
Eligibility
Primary outcome measure(s)
- Change in the eGFR slope — 1 year
To determine whether dapagliflozin is superior to standard of care only in reducing the eGFR slope. - Time to start of renal replacement therapy — 1 year
Kidney failure is defined as need for renal replacement therapy either by hemodialysis or kidney transplant
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Ain Shams University Hospitals | Cairo | Egypt | Recruiting |
More Ain Shams University trials in Egypt
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06982079 on ClinicalTrials.gov ↗ ← All trials in Egypt